Equities

Beyond Air Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Beyond Air Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.05
  • Today's Change0.03 / 2.94%
  • Shares traded580.50k
  • 1 Year change-85.86%
  • Beta0.4010
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.

  • Revenue in USD (TTM)5.80m
  • Net income in USD-36.70m
  • Incorporated2015
  • Employees61.00
  • Location
    Beyond Air Inc900 Stewart Ave, Suite 301GARDEN CITY 11530United StatesUSA
  • Phone+1 (516) 665-8200
  • Websitehttps://www.beyondair.net/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ALR Technologies SG Ltd9.49k-8.00m8.39m6.00------884.20-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
Nexalin Technology Inc156.94k-8.68m8.44m6.00--1.73--53.79-0.6345-0.63450.01090.26220.03020.300413.5926,156.67-167.17-166.16-178.46-334.5469.5176.06-5,530.09-1,178.9513.03--0.00--52.34-4.04-63.64------
SeaStar Medical Holding Corp881.00k-13.67m8.65m19.00--0.7138--9.82-16.43-16.430.68743.360.0876--6.1046,368.42-135.86---290.37--95.35---1,551.08--3.64--0.00------5.34------
AccuStem Sciences Inc0.00-1.61m8.95m2.00---------0.1163-0.11630.00-0.18110.00----0.00-192.46--------------------------26.60------
HeartSciences Inc8.67k-9.04m9.53m15.00--2.20--1,099.73-6.95-6.950.00571.360.00130.0056--578.00-131.22-145.78-202.97-316.2157.9056.93-104,225.80-42,610.782.00-10.000.1068---76.61-41.63-32.70--21.46--
Movano Inc500.00k-17.05m9.83m32.00------19.65-6.54-6.540.0883-2.040.04850.82163.5115,625.00-165.32-159.40-360.23-208.33-270.20---3,409.60-11,662.690.3451-12.462.32------18.97---9.25--
Bioelectronics Corp1.61m-289.82k9.88m9.00------6.14-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
BioRegenx Inc1.93m-18.93m10.00m5.00------5.19-0.0195-0.01950.002-0.00380.20833.1547.03385,874.00-204.29---341.72--78.14---980.96--0.0416-8.01-----31.40---540.38------
PAVmed Inc29.00k-595.00k10.40m39.0028.2428.50--358.78-0.6822-0.68220.00051.550.0009--3.05743.594.17-115.648.14-8,726.29-520.69--4,931.04-3,891.34----0.2111--22.15--148.24--15.12--
QHSLab Inc2.61m-386.75k10.85m4.00------4.15-0.0373-0.03730.1997-0.05421.4926.3812.80653,480.00-22.10-39.97---284.7966.3755.22-14.80-44.620.17140.30381.63--51.31--44.65------
Beyond Air Inc5.80m-36.70m11.06m61.00--0.6605--1.91-7.54-7.541.151.590.13822.608.0195,114.76-89.86-81.28-105.60-103.40-6.70---650.33-4,167.723.73-16.500.4351--219.6721.6622.60--166.66--
REMSleep Holdings Inc12.27k-3.01m11.15m6.00--46.21--908.37-0.0019-0.00190.000010.00020.01930.8251.51---472.04-107.16-671.87-177.2194.87---24,509.54-1,456.221.73--0.2146---42.47--39.36--5.18--
BioNano Genomics Inc28.72m-38.59m11.19m98.00--0.2149--0.3898-737.92-737.929.995.120.34511.455.84293,061.20-46.37-58.31-69.84-72.5345.9718.60-134.36-487.421.82--0.07---14.7924.8951.82--11.02--
SINTX Technologies Inc1.27m-16.56m11.69m20.00--2.70--9.21-6.93-6.930.58941.130.11211.345.5263,500.00-86.86-51.41-121.23-64.3452.0566.36-775.12-575.951.60-302.730.0143--9.9033.18-33.06--36.24--
Vicarious Surgical Inc0.00-53.59m12.95m123.00--0.7699-----9.04-9.040.002.360.00----0.00-97.47-35.33-109.17-37.33------------0.00------11.04---6.06--
Data as of Feb 13 2026. Currency figures normalised to Beyond Air Inc's reporting currency: US Dollar USD

Institutional shareholders

17.50%Per cent of shares held by top holders
HolderShares% Held
Alyeska Investment Group LPas of 30 Sep 2025759.06k9.48%
Balyasny Asset Management LPas of 03 Dec 2025297.44k3.71%
Bleichroeder LPas of 30 Sep 202586.49k1.08%
Avenue Capital Management II LPas of 03 Dec 202554.81k0.68%
Kingdon Capital Management LLCas of 30 Sep 202546.83k0.59%
Geode Capital Management LLCas of 30 Sep 202542.98k0.54%
Wealth Effects LLCas of 31 Dec 202531.68k0.40%
The Vanguard Group, Inc.as of 31 Dec 202530.53k0.38%
Vanguard Fiduciary Trust Co.as of 31 Dec 202529.37k0.37%
BlackRock Fund Advisorsas of 30 Sep 202522.03k0.28%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.